Related Experiment Video
Updated: Jul 8, 2026
09:12
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5
Bing Z Carter1, Duncan H Mak, Wendy D Schober
1The University of Texas M. D. Anderson Cancer Center, Housto 77030, USA.
Blood
|January 12, 2008
Summary
Triptolide combined with TRAIL synergistically induces apoptosis in acute myeloid leukemia (AML) cells. This combination overcomes resistance by modulating XIAP and p53 signaling, offering a novel AML treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Acute myeloid leukemia (AML) cells exhibit resistance to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
- Triptolide, an anticancer agent, has been shown to reduce XIAP levels in leukemic cells.
- XIAP (X-linked inhibitor of apoptosis protein) is implicated as a resistance factor in AML apoptosis.
Purpose of the Study:
- To evaluate the synergistic effect of combining triptolide with TRAIL in promoting apoptosis in AML cells.
- To investigate the roles of XIAP and p53 signaling in mediating resistance to TRAIL-induced apoptosis in AML.
- To explore novel therapeutic strategies for AML by overcoming apoptosis resistance mechanisms.
Main Methods:
- Assessing apoptosis induction in AML cells treated with triptolide and/or TRAIL.
- Utilizing XIAP-overexpressing and control cell lines (U937XIAP and U937neo) to evaluate XIAP's role.
- Employing small-molecule inhibitors (1396-11 for XIAP, nutlin3a for p53-MDM2 binding) and p53-knockdown/mutated cell models (OCI-AML3, U937).
Main Results:
- The combination of triptolide and TRAIL demonstrated synergistic apoptosis promotion in AML cells.
- Inhibition of XIAP enhanced TRAIL-induced apoptosis, confirming XIAP as a resistance factor.
- Triptolide increased DR5 (death receptor 5) levels, a process dependent on p53 signaling.
- Nutlin3a, by increasing p53 levels, also elevated DR5 and sensitized cells to TRAIL.
- Combined treatment with 1396-11, nutlin3a, and TRAIL showed superior efficacy compared to dual combinations.
Conclusions:
- Triptolide acts as a sensitizer to TRAIL-induced apoptosis in AML, partly by modulating XIAP expression and p53 signaling.
- The combination of triptolide and TRAIL presents a promising novel therapeutic strategy for AML by overcoming apoptosis resistance.
- Targeting XIAP and p53 pathways concurrently with TRAIL offers a multi-pronged approach to enhance anti-leukemic effects.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...